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Abstract
The quality of antigen specific CD8+ T cell responses is central to immune efficacy in infectious 
and malignant settings. Inducing effector CD8+ T cells with potent functional properties is 
therefore a priority of immunotherapy. However, the optimal assessment of new therapeutic 
molecules or strategies in humans is limited by the models currently used. Here, we introduce an 
original model of in vitro CD8+ T cell priming, based on an accelerated dendritic cell coculture 
system, which uses unfractionated human PBMCs as the starting material. This approach allows 
for a rapid study of adjuvant effects on the functional properties of human CD8+ T cells, primed 
from antigen-specific naïve precursors. We demonstrate that a selective TLR8 agonist, in 
combination with FLT3L, primes high-quality CD8+ T cell responses. TLR8L/FLT3L primed 
CD8+ T cells displayed enhanced cytolytic activity, polyfunctionality and antigen sensitivity. The 
acquisition of this superior functional profile was associated with increased T-bet expression in T 
cells induced via an IL-12-dependent mechanism. Collectively, these data validate an expedited 
route to vaccine delivery or optimal T cell expansion for adoptive cell transfer.
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Introduction
Cytotoxic activity, polyfunctionality and antigen sensitivity predict CD8+ T cell efficacy 
against infected or dysregulated cells (1, 2). Potent cytolytic activity is indeed necessary for 
the elimination of cancerous or infected cells. Meanwhile, demonstrations of the combined 
action of the cytokines interferon-ͥ (IFNͥ) and tumour necrosis factor (TNF) in inducing 
permanent growth arrest in cancers, or in anti-viral processes, has highlighted the 
importance of T cell polyfunctionality (i.e. their capacity to produce multiple effector 
cytokines simultaneously) (3). Lastly, high levels of antigen sensitivity endow T cells with 
the capacity to recognize cognate peptide-major histocompatibility class I (pMHCI) 
complexes at low densities on the target cell surface, and thus to act swiftly against infected 
cells or to break tolerance associated with cancer (4). However, the induction of de novo 
CD8+ T cell responses with such protective attributes in humans has proven difficult through 
vaccination (5, 6), and remains also a major goal for adoptive cell therapy. Dendritic cells 
(DCs) govern the nature of CD8+ T cell responses primed from naïve precursors, via the 
provision of processed antigens in the form of pMHCI molecules, together with other 
important signals, including costimulatory interactions and inflammatory cytokines. Much 
effort has therefore been devoted to the modulation of DC function for the optimization of 
CD8+ T cell immunity (7). Adjuvants, such as Toll-like receptor (TLR) ligands, can improve 
the immunogenicity of soluble protein and peptide antigens by mimicking pathogen-
associated “danger” signals (8, 9), and may thus prove useful contributors to the success of 
immunotherapy.
However, it is difficult to study the effects of potential adjuvants on human CD8+ T cell 
responses due to the lack of a suitable model. Although the widespread use of murine 
systems has greatly advanced our knowledge of TLR function and DC/T cell interactions, 
there are significant biological differences between mice and humans that complicate simple 
extrapolation between species. For instance, the cellular distribution of TLR8 is entirely 
different between humans and mice, and is considered to be non-functional in the latter (10). 
As a consequence, the adjuvant properties of TLR8-selective agonists have not been fully 
assessed (11, 12). Moreover, traditional in vitro priming protocols that use human material 
rely on populations of inflammatory monocyte-derived DCs (moDCs) generated in a two-
stage process from peripheral blood mononuclear cell (PBMC)-purified CD14+ monocytes 
(13). In this setting, differentiation is achieved using a combination of GM-CSF and IL-4 
prior to maturation with a cocktail of inflammatory cytokines or lipopolysaccharide (LPS) 
(14, 15). Although adequate for many purposes, this strategy has a number of limitations. In 
particular, the initial preparation of moDCs is laborious and time consuming. More 
importantly, it is limited to one subset of antigen presenting cells, and no attempt is made to 
evaluate the role of conventional DCs and other resident blood cells (e.g. CD4+ T cells and 
NK cells) in the priming process.
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To circumvent these drawbacks, we developed an innovative model of human CD8+ T cell 
priming. This original in vitro approach is based on the rapid mobilization of DCs directly 
from unfractionated PBMCs, adapted from an earlier method designed to detect low-
frequency memory T cell responses (15). This new approach enables side-by-side studies of 
multiple test parameters in a standardized system with quantitative and qualitative readouts 
of the primed antigen-specific CD8+ T cell response. Here, we used our system to compare 
conventional adjuvant combinations alongside the largely uncharacterized ssRNA40 TLR8 
ligand (TLR8L), and to reveal the potential benefit of this agonist for the induction of high 
quality human effector CD8+ T cells.
Materials and Methods
Flow cytometry reagents
Standard and CD8-null ELA/HLA-A2 tetramers were produced as described previously (16, 
17). The CD8-null ELA/HLA-A2 complex incorporates a compound D227K/T228A 
mutation in the ͣ3 domain that abrogates CD8 binding without impacting on the TCR 
docking platform (18). Directly conjugated monoclonal antibodies (mAbs) were purchased 
from commercial sources as follows: (i) ͣ-CD8-APC-Cy7, ͣ-CD45RA-V450, ͣ-CCR7-PE-
Cy7, ͣ-CD107a-PE-Cy5, ͣ-IFNͥ-AlexaFluor700, ͣ-TNF-PE-Cy7 and ͣ-granzyme-B-
V450 (BD Biosciences); (ii) ͣ-CD3-ECD (Beckman Coulter); (iii) ͣ-CD28-AlexaFluor700 
(BioLegend); (iv) ͣ-T-bet-AlexaFluor647 (eBiosciences); (v) ͣ-MIP-1ͤ-FITC (R&D 
Systems); (vi) ͣ-IL-2-APC (Miltenyi Biotec); and (vii) ͣ-perforin-BD48-FITC (Abcam). 
The amine-reactive viability dye Aqua (Life Technologies) was used to eliminate dead cells 
from the analysis. Intracellular staining for T-bet was performed using the Transcription 
Factor Buffer Set (BD Pharmingen) according to the manufacturer’ s instructions. 
Intracellular staining for granzyme B and perforin-BD48 was compatible with this 
procedure. Staining with all other reagents was conducted according to standard protocols 
(19, 20). Data were acquired using an LSR Fortessa flow cytometer (BD Biosciences) and 
analyzed with FlowJo software version 9.3.7 (TreeStar Inc.).
Peptides
All peptides were synthesized commercially at >95% purity (Biosynthesis Inc.). The 
ELA-10 peptide (ELAGIGILTV; Melan-A/MART-1 residues 26-35A27L) was used to pulse 
target cells in functional assays. The ELA-20 peptide (YTAAEELAGIGILTVILGVL; 
Melan-A/MART-1 residues 21-40A27L) was used for in vitro priming. The ELA-20Ct 
peptide (GHGHSYTAAEELAGIGILTV; Melan-A/MART-1 residues 16-35A27L) was tested 
in early presentation and stability experiments (Supplemental Figure 1).
PBMCs and cell lines
Peripheral blood mononuclear cell (PBMC) samples were obtained from healthy HLA-A2+ 
individuals via standard protocols and cryopreserved before use in CD8+ T cell priming 
assays. The ELA-specific CD8+ T cell line Mel9916 was generated by in vitro priming and 
purified by flow cytometric sorting of ELA/HLA-A2 tetramer+ events. An HLA-A2+ 
Epstein-Barr virus (EBV)-transformed B-lymphoblastoid cell line (B-LCL) was used to 
present the ELA-10 peptide in activation assays. The HLA-A2+ tumor cell line Me275 was 
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used to present the naturally processed Melan-A/MART-1 epitope (AAGIGILTV; Melan-A/
MART-1 residues 27-35). The HLA-A2+ Melan-A/MART-1− tumor cell line Me241 was 
used as a negative control.
In vitro priming of naïve Melan-A/MART-1 antigen-specific CD8+ T cells
Naïve precursors specific for the HLA-A2-restricted Melan-A/MART-1 epitope ELA 
(ELAGIGILTV; Melan-A/MART-1 residues 26-35A27L) were primed in vitro using an 
accelerated dendritic cell coculture protocol. Thawed PBMCs were resuspended in AIM 
medium (Invitrogen), supplemented with either GM-CSF (1000 IU/mL; Miltenyi Biotec) 
and IL-4 (500 IU/mL; Invivogen) or FLT3L (50 ng/mL; R&D Systems), and plated out at 
5×106 cells/well in a 24-well tissue culture plate (day 0). After 24 hours (day 1), maturation 
of resident dendritic cells (DCs) was induced under one of the following conditions: (i) a 
standard cocktail of inflammatory cytokines comprising TNF (1000 U/mL), IL-1ͤ (10 ng/
mL), IL-7 (0.5 ng/mL) and prostaglandin E2 (PGE2; 1 μM) (R&D Systems) (15); (ii) LPS 
(0.1 μg/mL; Invivogen); or (iii) ssRNA40 (0.5 μg/mL; Invivogen). The ELA-20 peptide was 
added together with the DC maturation reagents at a final concentration of 1 μM. On day 2, 
fetal calf serum (FCS; Gibco) was added to 10% by volume per well. Fresh RPMI-1640 
(Gibco) enriched with 10% FCS was used to replace the medium every 3 days. ELA-specific 
CD8+ T cell frequency and phenotype were typically determined on day 10. Purified naïve 
and memory CD8+ T cell subsets (Supplemental Figure 2) were obtained using the T cell 
Enrichment Column Kit (R&D Systems). An unconjugated ͣ-IL-12p70 blocking antibody 
(R&D Systems) was added at a final concentration of 10 μg/mL on days 0, 1 and 2 in later 
priming experiments (Figure 6). A monoclonal mouse IgG1 isotype control antibody was 
used in the non-blocking conditions (ͣ-IL-12−).
Polyfunctionality assay
ELA-primed PBMCs containing approximately 5×104 ELA/HLA-A2 tetramer+ CD8+ T 
cells were incubated with ELA-10 peptide-pulsed HLA-A2+ B-LCL target cells at an 
effector to target (E:T) ratio of 1:10 in the presence of ͣ-CD107a for 6 hours at 37°C. 
Monensin (2.5 μg/mL; Sigma-Aldrich) and brefeldin A (5 μg/mL; Sigma-Aldrich) were 
added for the final 5 hours. Parallel assays were conducted with unpulsed HLA-A2+ B-LCL 
target cells to evaluate non-specific background activation. Intracellular cytokine staining 
was performed as described previously (21). Data were acquired using an LSR Fortessa flow 
cytometer (BD Biosciences) and analyzed with FlowJo software version 9.3.7 (TreeStar 
Inc.). Pie charts were constructed using SPICE software (NIAID) and polyfunctionality 
indices were calculated as described previously (22).
Fluorometric assessment of T-lymphocyte antigen-specific lysis (FATAL) cytotoxicity assay
ELA-10 peptide-pulsed HLA-A2+ B-LCL target cells were labeled with Pacific Blue 
succinimidyl ester (PBSE; 10 μM) to allow flow cytometric separation from unpulsed HLA-
A2+ B-LCL control cells, which were left unlabeled (PBSE−). 104 PBSE+ target and 104 
PBSE− control cells were incubated with CD8-enriched PBMCs containing 5×104 primed 
ELA-specific CD8+ T cells for 12 hours at 37°C. Control assays were set up in parallel 
either without effectors or with non-cognate CD8+ T cells at the same E:T ratio (5:1). After 
harvesting, cells were stained with Aqua, ͣ-CD3-ECD, ͣ-CD8-APC-Cy7 and ͣ-CD19-
Lissina et al. Page 4
J Immunol. Author manuscript; available in PMC 2016 July 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
FITC prior to acquisition using an LSR Fortessa flow cytometer (BD Biosciences). Lytic 
activity was calculated as a function of PBSE+ target cell elimination relative to internal 
PBSE− control cells.
Statistical analysis
Comparisons between groups were performed using the Wilcoxon signed rank test in Prism 
5 (GraphPad). P values <0.05 were considered significant.
Results
Design of an accelerated DC coculture system for the priming of T cells in vitro
The experimental outline of our new priming approach, starting from unfractionated 
PBMCs, is summarized in Figure 1A. As circulating human DCs are rare, precursors (in 
particular CD14+ monocytes) within the starting PBMC material were mobilized using GM-
CSF/IL-4 and matured with a cocktail of inflammatory cytokines including TNF, IL-1ͤ and 
PGE2. IL-7 was also added to provide an additional co-stimulatory signal to naïve T cells, 
and facilitate their priming upon antigen-driven activation, as previously described during 
the optimization of our accelerated dendritic cell coculture protocol (15, 23). Alternatively, 
DC mobilization was achieved by exposure of PBMCs to FLT3 ligand (FLT3L), which has 
demonstrable T cell priming efficacy in animal studies (24). GM-CSF/IL-4 and FLT3L have 
been shown to act on various immune cell subsets and mobilize distinct populations of DCs 
(25-27). To ensure that sufficient numbers of antigen-specific CD8+ T cells were present in 
the naïve pool for priming, we focused our analysis on the Melan-A/MART-1 epitope 
(EAAGIGILTV26-35), used here as a model antigen, since it is recognized at remarkably 
high precursor frequencies in HLA-A*0201+ (HLA-A2+) individuals (28, 29). This large 
specific TCR repertoire in the naïve CD8+ T cell compartment provides a useful tool for the 
study of human antigen-specific T cell priming. Additionally, the polyclonal nature of this 
Melan-A specific population presents an advantage over the TCR transgenic experimental 
mouse models that are typically employed for the study antigen-driven adaptive immunity 
(30, 31). To ensure optimal immunogenicity, we used the heteroclitic sequence of the 
epitope: ELAGIGILTV (ELA) (32). Moreover, the ELA epitope was incorporated into a 
20mer synthetic long peptide (SLP, ELA-20) as a means of limiting antigen display to DCs 
with cross-presentation capacity (33-35). Prior to experimentation, we verified that the 
ELA-20 peptide required active processing. Specifically, we showed that ELA-20 was not 
presented directly by HLA-A2 (Supplemental Figure 1A) and was not subjected to non-
specific cleavage by enzymes present in serum (Supplemental Figure 1B).
Next, we evaluated the optimal parameters for ELA-specific CD8+ T cell priming in our 
system. An ELA-20 concentration of 1 μM consistently generated sufficiently large 
populations of primed cells for functional characterization (data not shown), and was 
therefore chosen for all downstream assays. Primed ELA-specific CD8+ T cells peaked on 
day 10 (Figure 1B), following identical kinetics and achieving comparable magnitudes with 
both the GM-CSF/IL-4 and FLT3L protocols (Supplemental Figure 2A). Subsequent 
experiments were therefore conducted over this time frame. We also confirmed that primed 
ELA-specific CD8+ T cells originated from the naïve pool, by showing that ELA/HLA-A2 
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tetramer+ T cells were expanded from purified naïve (CCR7+ CD45RA+) but not memory 
CD8+ T cells (Supplemental Figures 2B and 2C). After priming, the vast majority of ELA/
HLA-A2 tetramer+ CD8+ T cells displayed phenotypic hallmarks of antigen-driven 
expansion, predominantly differentiating into the effector memory (CCR7− CD45RA−) 
compartment (Supplemental Figures 2D and 2E). No differences in terms of differentiation 
status were observed between ELA-specific CD8+ T cell populations primed with either 
GM-CSF/IL-4 or FLT3L (Supplemental Figure 2E).
Human CD8+ T cell priming with a TLR8 selective agonist
In subsequent experiments, we used our validated system to study the effect of a recently 
available TLR8L (ssRNA40), in comparison with the standard cocktail of inflammatory 
cytokines (TNF, IL-1ͤ, PGE2 and IL-7), or with LPS, an extensively studied TLR4 ligand 
(TLR4L). Either TLR4L or TLR8L was introduced during the DC maturation step, in lieu of 
the inflammatory cytokine cocktail. Tetramer-based enumeration of ELA-specific CD8+ T 
cell populations expanded in parallel revealed no major differences in the magnitude of 
priming across the three maturation conditions tested (Figure 1C). However, the GM-CSF/
IL-4/TLR8L combination primed significantly fewer ELA-specific CD8+ T cells compared 
to the FLT3L/TLR8L combination, highlighting differences in the way that GM-CSF/IL-4 
and FLT3L modulate subsets of antigen-presenting cells. To support this point, we subjected 
purified CD14+ monocytes to GM-CSF/IL-4 or FLT3L, before introducing different 
maturation factors into the culture medium (Supplemental Figure 3). As expected, GM-CSF/
IL-4 but not FLT3L, treatment resulted in the differentiation of the monocytes into moDCs 
(with the downregulation of CD14 from the surface of GM-CSF/IL-4 treated cells). 
However, while our cytokine cocktail or TLR4L induced the maturation of these cells 
(measured by the upregulation of HLA-DR and CD86 on the surface of moDCs), TLR8L 
had no effect. The failure of GM-CSF/IL-4-induced moDCs to respond to TLR8L 
stimulation (despite them being known to express TLR8), provides one potential explanation 
for the poor T cell priming capacity of the GM-CSF/IL-4/TLR8L combination in our 
system. These findings highlight the limitations of the widespread use of moDCs, and 
question the suitability of these in vitro generated inflammatory cells for the study of 
potential adjuvants. This observation provides an additional argument in favour of using a 
system of unfractionated PBMCs as an alternative to isolated moDCs, the use of which 
would have overlooked the FLT3L/TLR8L effect on T cell priming. Notably, the FLT3L/
TLR8L-primed ELA-specific CD8+ T cells possessed significantly greater cytotoxic 
potential, assessed by the expression of granzyme B and perforin, than cells primed in the 
other conditions (Figures 2A and 2B). This observation was confirmed in antigen-presenting 
cell lysis assays, whereby CD8+ T cells primed in the presence of FLT3L/TLR8L, killed 
more than twice as many target cells loaded with 1 μM ELA-10 than was achieved by CD8+ 
T cells primed under any other condition (Figures 2C and 2D). Moreover, only FLT3L/
TLR8L-primed CD8+ T cells were capable of eliminating targets presenting ELA-10 at a 
concentration of 10 nM.
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Qualitatively superior human CD8+ T cell responses primed with an FLT3L/TLR8L 
combination
Next, we assessed the ability of primed CD8+ T cells to deploy multiple effector functions in 
response to antigen encounter. In these assays, we measured the simultaneous induction of 
IFNͥ, MIP-1ͤ, TNF and IL-2, together with surface mobilization of CD107a (Figure 3A). 
Although GM-CSF/IL-4 and FLT3L in conjunction with the cytokine cocktail generated 
ELA-primed CD8+ T cells expressing similar levels of cytotoxic molecules (Figures 2A and 
2B), FLT3L treatment elicited greater frequencies of polyfunctional cells compared to GM-
CSF/IL-4 (Figure 3B top row). Moreover, ELA-specific CD8+ T cells primed using the 
FLT3L/TLR8L combination displayed the highest levels of polyfunctionality (Figure 3B). 
These differences were statistically significant in terms of the calculated polyfunctionality 
index across individual PBMC donors (Figure 3C).
Antigen sensitivity, a major determinant of CD8+ T cell functional attributes, was evaluated 
via cognate peptide titration in IFNͥ secretion assays. FLT3L/TLR8L-primed ELA-specific 
CD8+ T cells displayed the highest antigen sensitivity, with a typical EC50 value (7.45×10−9 
M) approximately one or two orders of magnitude lower compared to the GM-CSF/IL-4/
TLR4L (5.77×10−8 M) or FLT3L/cytokine (1.36×10−7 M) combinations, respectively 
(Figure 4A). IFNͥ production by GM-CSF/IL-4/cytokine-primed ELA-specific CD8+ T 
cells was negligible. These differences in antigen sensitivity between conditions extended 
across the full spectrum of effector functions, enabling FLT3L/TLR8L-primed CD8+ T cells 
to deploy multiple effector functions at ELA-10 peptide concentrations as low as 1 nM 
(Figure 4B), equivalent to the amount of antigen presented in physiological settings. 
Crucially, FLT3L/TLR8L-primed ELA-specific CD8+ T cells were indeed capable of 
mounting polyfunctional responses to an HLA-A2+ melanoma cell line naturally expressing 
the endogenous Melan-A/MART-1 antigen (Figure 4C). In contrast, the same tumor cell line 
was not recognized efficiently by ELA-specific CD8+ T cells primed under other test 
conditions (Figure 4C).
Mechanistic insights into TLR8L mediated adjuvant effects
We then decided to explore the mechanisms involved in the acquisition of superior 
functional attributes by FLT3/TLR8L-primed CD8+ T cells. It is established that T cell 
receptor (TCR) avidity, defined as the collective affinities of multiple monomeric TCR/
pMHC interactions, can greatly influence antigen sensitivity and thereby dictate the 
functional profile of CD8+ T cells in response to cognate antigen (21, 36). Accordingly, we 
used standard and CD8-null ELA/HLA-A2 tetramers in parallel to quantify this parameter 
across different priming conditions (Figure 5A). CD8-null tetramers are characterized by 
their inability to bind the CD8 coreceptor, thereby enabling the selective detection of high 
avidity cells among total antigen-specific CD8+ T cells (identified with standard reagents) 
(17). Besides a small increase in TCR avidity within the FLT3/TLR8L-primed CD8+ T cell 
population, no statistically significant differences in TCR avidity were detected across any 
of the test conditions (Figure 5B).
The expression of effector molecules such as granzyme B, perforin and IFNͥ is tightly 
controlled in CD8+ T cells by the T-box transcription factor T-bet (also known as Tbx-21) 
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(37). We therefore assessed the intracellular expression of T-bet in CD8+ T cells upon 
priming. Significantly higher T-bet expression levels were detected in ELA-specific CD8+ T 
cells primed with FLT3L/TLR8L compared to other combinations (Figures 5C and 5D). An 
important regulator of T-bet expression is IL-12 (38), which is known to be secreted by 
myeloid DCs upon TLR8 ligation (11). To assess the relationship between IL-12 levels and 
T-bet induction in our in vitro priming system, an ͣ-IL-12p70 blocking antibody was 
administered daily during the first three days of culture. This intervention led to a significant 
drop in T-bet levels in FLT3L/TLR8L-primed CD8+ T cells (Figures 6A and 6B). Moreover, 
ELA-specific CD8+ T cells primed in the presence of the ͣ-IL-12p70 blocking antibody 
expressed considerably less granzyme B and perforin (Figure 6C), and were also less 
polyfunctional (Figure 6D). In our system, IL-12 appears therefore to be a key factor for 
driving T-bet expression in CD8+ T cells primed in the presence of TLR8L, and 
consequently an indirect enhancer of their effector functions.
Discussion
We report here that human PBMCs mobilized with GM-CSF/IL-4 or FLT3L responded 
differently to maturation signals such as cytokines or TLR ligands, affecting the quality of 
the primed CD8+ T cell responses. Importantly, the combined use of FLT3L and TLR8L 
resulted in the priming of antigen-specific CD8+ T cells displaying robust effector functions, 
showing for the first time that a selective TLR8 agonist can act as a potent adjuvant to prime 
functionally superior antigen-specific human CD8+ T cells. Collectively, our data indicate 
that TLR8L, through effects on FLT3L (but not GM-CSF/IL-4) -mobilized DCs, triggers T-
bet expression in primed CD8+ T cells through an IL-12 dependent mechanism. In turn, T-
bet endows these CD8+ T cells with superior antigen sensitivity, robust cytolytic activity and 
polyfunctionality. We also demonstrate that the high antigen sensitivity of FLT3L/TLR8L-
primed CD8+ T cells does not arise through the selection of T cells bearing high avidity 
TCRs during the priming process. Instead, this gain in antigen sensitivity may be explained 
by a reduction in TCR/pMHCI activation thresholds experienced by FLT3L/TLR8L primed 
cells (due to heightened T-bet expression, induced by IL-12), leaving them poised for 
antigen-driven activation.
These new findings were made possible owing to the development of an original in vitro 
priming model that offers several practical and theoretical advantages over existing systems. 
In addition to streamlining the search for more effective adjuvants, our approach is 
applicable to several notable challenges in the field. The use of unmanipulated PBMCs 
(which also includes cord or elderly blood samples) in our system will likely aid in the 
identification of immunization regimens suitable for individuals who are typically refractory 
to priming with standard vaccines, for instance at the extremes of age or with advanced HIV 
infection. Moreover, our priming model can be of use to the study of mechanisms 
underlying effective T cell priming (e.g. to identify the DC subsets or molecular pathways 
involved). For instance, preliminary data using our approach imply that DCs from the 
myeloid lineage are most likely to be involved in FLT3L/TLR8L-mediated T cell priming. In 
contrast to the GMCSF receptor (CD116), FLT3 (CD135) was not expressed on CD14+ 
monocytes, but was instead localised to plasmacytoid and myeloid DCs (pDCs and mDCs, 
respectively, data not shown), implicating these DC subsets in the FLT3L-mediated priming 
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process. Furthemore, experiments involving the magnetic depletion of various microbead-
bound antigen presenting cell subsets prior to priming initiation showed no influence of 
CD14+ monocytes or pDCs on ELA-specific CD8+ T cell priming with the FLT3L/TLR8L 
combination. Meanwhile, the depletion of mDCs had a negative impact on priming (carried 
out in the presence of FLT3L and TLR8L) in some experiments, suggesting a potential 
involvement of mDCs (data now shown). Overall, we view it as being likely that mDCs 
(rather than pDCs) play at least a partial role in CD8+ T cell priming in the presence of 
FLT3L and TLR8L, consistent with the fact that TLR8 is expressed by mDCs, but not pDCs. 
However, it is highly likely that other DC subsets hold the potential to prime CD8+ T cells in 
these same culture conditions. For instance, FLT3L was recently reported to mobilize a rare 
population of circulating mDC precursors (39), which could play this role. Finally, our 
model could also facilitate the selection of antigen formulations best suited to the induction 
of highly functional de novo T cell responses. The use of SLPs, which display several 
beneficial features for CD8+ T cell priming compared to short peptides (34, 35, 40, 41), 
serves as one such example.
We envisage that the in vitro priming approach presented in this study is useful for screening 
candidate antigens and adjuvants for vaccination in humans. For instance, the present data 
encourage further testing of the adjuvant potential and inflammatory properties of a selective 
TLR8 agonist in in vivo models. Recent work in transgenic mice, expressing different levels 
of human TLR8, supports a role for this receptor in autoimmune inflammation, advocating 
potentially adverse effects of TLR8L use in humans (42). However, these inflammatory side-
effects may be averted through the specific targeting of such an adjuvant directly to lymph 
nodes, using delivery agents such as amphiphiles (i.e. linking the antigen and adjuvant to a 
lipophilic albumin-binding tail) or nanoparticles (43, 44). These approaches could be called 
upon to decrease the systemic dissemination and potential toxicity of TLR8L, while 
boosting CD8+ T cell priming efficacy. In light of our findings, investigating the adjuvant 
potential of other TLR8 (e.g. ssPoly(U) or benzoazepine analog TL8-506) or TLR7/8 (e.g. 
imidazoquinoline R848 or thiazoquinolone CL075) specific ligands using our approach will 
be important. Differences in potency or unexpected antagonizing effects (e.g. between TLR7 
and TLR8 signalling pathways) might be observed. The present in vitro priming system may 
also expedite the generation of potent T cells for adoptive cell therapy. It is notable in this 
respect that FLT3L/TLR8L-primed antigen-specific CD8+ T cells recognized naturally 
presented antigens on a tumor cell line and exhibited properties associated with in vivo 
efficacy. Overall, the present findings are directly relevant to our understanding of effector T 
cell generation and the development of effective immunotherapy in humans.
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Figure 1. In vitro CD8+ T cell priming and magnitude of TLR8L primed antigen specific cells
A. Outline of the in vitro CD8+ T cell priming system using unfractionated PBMC samples. 
B. Representative flow cytometry data showing the kinetics of ELA-specific CD8+ T cell 
priming in the presence of GM-CSF/IL-4 and a cocktail of inflammatory cytokines. Plots are 
gated on viable CD3+ lymphocytes after aggregate exclusion. Numbers refer to percentages 
of ELA-HLA-A2 tetramer+ cells within the total CD8+ T cell population. C. Response 
magnitudes for ELA-specific CD8+ T cell populations primed under different conditions 
from several healthy HLA-A2+ donor PBMC samples. Antigen only (no maturation signal), 
cytokine cocktail (TNF, IL-1ͤ, PGE2 and IL-7), TLR4L (LPS) or TLR8L (ssRNA40) were 
each used in combination with either GMCSF/IL-4 or FLT3L supplementation. Horizontal 
bars indicate median values. Statistical comparisons between groups were performed using 
the Wilcoxon signed rank test; *P < 0.05.
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Figure 2. Greater cytotoxic potential of CD8+ T cells primed in vitro with an FLT3L/TLR8L 
combination
A. Representative flow cytometry plots showing granzyme B (top panel) or perforin (bottom 
panel) expression by ELA-specific CD8+ T cells primed under different conditions. B. 
Granzyme B (top graph) and perforin (bottom graph) expression by ELA-specific CD8+ T 
cells primed under different conditions from several healthy HLA-A2+ donor PBMC 
samples. Horizontal bars indicate median values. Statistical comparisons between groups 
were performed using the Wilcoxon signed rank test; *P < 0.05, **P < 0.01, ***P < 0.001. 
C. Representative flow cytometry data from a FATAL cytotoxicity assay showing the 
disappearance of ELA peptide-pulsed PBSE+ HLA-A2+ B-LCL target cells relative to non-
peptide-pulsed PBSE- HLA-A2+ B LCL control cells in the presence of ELA-specific CD8+ 
T cells primed under different conditions. Numbers indicate the percentages of control 
(upper left) and target (upper right) B-LCL cells. D. Specific lysis of HLA-A2+ B-LCL 
target cells presenting the indicated concentrations of exogenously-loaded ELA peptide in 
the presence of ELA-specific CD8+ T cells primed under different conditions. A non-
cognate population of CD8+ T cells derived from the same HLA-A2+ donor and cultured 
under similar conditions to the ELA-specific CD8+ T cell population was used as a control. 
Error bars represent SD from the mean of two replicates.
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Figure 3. Polyfunctionality of FLT3L/TLR8L primed CD8+ T cells
A. Representative flow cytometry plots showing cytokine production (IFNͥ, MIP-1ͤ, TNF 
and IL-2) and degranulation (CD107a) in response to antigen stimulation. ELA-specific 
CD8+ T cells primed under the indicated conditions were incubated with media alone (top 
row) or ELA peptide-pulsed HLA-A2+ B-LCL target cells (middle and bottom rows). 
Primed ELA-specific CD8+ T cells were quantified as tetramer+ cells within the total CD8+ 
population (left column). Function plots are gated on viable CD3+ CD8+ tetramer+ 
lymphocytes (middle and right columns). Numbers in each quadrant refer to the percentages 
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of primed ELA-specific CD8+ T cells expressing the indicated combinations of functions. B. 
Averaged pie chart representations of background-adjusted polyfunctional profiles for ELA-
specific CD8+ T cells primed under different conditions from 10 healthy donors. Pie 
segments and colours correspond to the proportions of ELA-specific CD8+ T cells 
expressing the indicated number of functions, respectively. C. Polyfunctionality indices for 
ELA-specific CD8+ T cell populations, calculated from the data depicted in (B). Horizontal 
bars indicate median values. Statistical comparisons between groups were performed using 
the Wilcoxon signed rank test; *P < 0.05, ***P < 0.001.
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Figure 4. High antigen sensitivity of FLT3L/TLR8L primed CD8+ T cells
A. Normalized IFNͥ production curves for ELA-specific CD8+ T cells primed under 
different conditions. HLA-A2+ B-LCL target cells were pulsed with ELA peptide across a 
range of concentrations and used to stimulate ELA-specific CD8+ T cells in standard 
intracellular cytokine staining assays. Data are representative of two independent 
experiments B. Polyfunctional profiles of ELA-specific CD8+ T cells primed under the 
indicated conditions. HLA-A2+ B-LCL target cells were pulsed with ELA peptide across a 
range of concentrations and used to stimulate ELA-specific CD8+ T cells prior to flow 
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cytometric analysis. C. Polyfunctional profiles of ELA-specific CD8+ T cells responding to 
natural levels of the Melan-A/MART-1 antigen presented by an HLAA2+ melanoma cell 
line. An HLA-A2+ Melan-A/MART-1− tumor cell line was used as a negative control (data 
not shown). Data in (B) and (C) are depicted in pie chart representations averaged from two 
independent experiments conducted with HLA-A2+ PBMCs from two different donors with 
frequencies of expanded cells equivalent in the different conditions tested.
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Figure 5. TCR avidity and T-bet expression in in vitro primed CD8+ T cells
A. Representative flow cytometry plots showing standard or CD8-null ELA/HLA-A2 
tetramer staining of primed ELA-specific CD8+ T cells. Plots are gated on viable CD3+ 
lymphocytes after aggregate exclusion. Numbers refer to percentages of tetramer+ cells 
within the total CD8+ population. B. Percentages of high avidity ELA-specific CD8+ T cells 
primed using either GMCSF/IL-4 or FLT3L in combination with a cocktail of inflammatory 
cytokines (TNF, IL-1ͤ, PGE2 and IL-7) or TLR ligands. These percentages were calculated 
from the corresponding CD8-null/standard ELA/HLA-A2 tetramer+ cell ratios. Data are 
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averaged over four independent experiments. Error bars represent SD from the mean. C. 
Representative flow cytometry plots showing intracellular T-bet expression (white 
histograms) by ELA-specific CD8+ T cells primed under different conditions. Grey 
histograms depict isotype control staining and vertical dotted lines indicate the mean 
fluorescence intensity (MFI) of T-bet staining for the weakest priming condition. D. 
Intracellular T-bet expression by ELA-specific CD8+ T cells primed under different 
conditions. Horizontal bars indicate median values. Statistical comparisons between groups 
were performed using the Wilcoxon signed rank test; *P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 6. IL-12 dependent functional quality of FLT3L/TLR8L-primed CD8+ T cells
A. Representative flow cytometry plots showing intracellular T-bet expression (white 
histograms) by ELA-specific CD8+ T cells primed with FLT3L plus the indicated maturation 
signals in the presence of an ͣ-IL-12p70 blocking antibody or a mouse IgG1 isotype control 
antibody. Grey histograms depict isotype control staining and vertical dotted lines indicate 
the mean fluorescence intensity (MFI) of T-bet staining for the weakest priming condition. 
B. Intracellular T-bet expression by ELA-specific CD8+ T cells primed under different 
conditions. Horizontal bars indicate median values. C. Granzyme B (top graph) and perforin 
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(bottom graph) expression by ELA-specific CD8+ T cells primed as in (B). Data are 
averaged over eight independent experiments. Error bars indicate SD from the mean. 
Statistical comparisons between groups were performed using the Wilcoxon signed rank 
test; *P < 0.05, **P < 0.01, ***P < 0.001. D. Polyfunctional profiles of ELA-specific CD8+ 
T cells primed as in (B). Data are averaged over two independent experiments with ELA 
peptide-pulsed HLA-A2+ B-LCL target cells.
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